Syndax Pharmaceuticals Ownership

The majority of Syndax Pharmaceuticals outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Syndax Pharmaceuticals to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Syndax Pharmaceuticals. Please pay attention to any change in the institutional holdings of Syndax Pharmaceuticals as this could imply that something significant has changed or is about to change at the company. Some institutional investors establish a significant position in stocks such as Syndax Pharmaceuticals in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Syndax Pharmaceuticals, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits. Dividends Paid is likely to drop to about 2.1 M in 2024. Dividend Yield is likely to drop to 0.02 in 2024. Common Stock Shares Outstanding is likely to drop to about 38.8 M in 2024. Net Loss is likely to rise to about (127.7 M) in 2024. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Syndax Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. For more information on how to buy Syndax Stock please use our How to Invest in Syndax Pharmaceuticals guide.